Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Updated: J&J Moves Closer To PFA Approval; New Data Presented At Boston AF

Executive Summary

The AF Symposium in Boston Featured presentations of two trials of Johnson & Johnson/Biosense Webster’s Varipulse pulsed field ablation system and more safety data from the ADVENT trial of Boston Scientific’s Farapulse PFA.

You may also be interested in...



News We’re Watching: Boston Scientific Updates PFA Progress, Novel Vibrating Pill For Obesity, And More

Medtech Insight's News We're Watching highlights medtech industry developments that you may have missed over the last few weeks. The first edition for 2024 includes an update on Boston Scientific's pulsed field ablation technology and a preclinical trial of a novel weight-loss "pill." Also, Strkyer is acquiring SERF, Imperative Care is testing a new intracranial stent, and CardioMech closed a $13m funding round to support its artificial mitral chord repair technology.

First PFA In The US: FDA Approves Medtronic’s PulseSelect For AF Ablation

Medtronic's PulseSelect is the first pulse field ablation technology to earn FDA approval and the company plans to launch it in early 2024. PulseSelect PFA earned a CE mark in November.

News We’re Watching: Philips And Walgreens Settlements, ReCor Readies For Takeoff, Farapulse Trial Results

This week, Philips announced a legal settlement on recalled CPAPs and BiPAPs; the FDA released emergency preparation recommendations; ReCor prepared to bring Paradise RDN to the US market; and Abbott released the results of a trial comparing optical coherence tomography (OCT) to angiography for guidance during cardiac surgery.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT154407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel